What Trump’s New Drug Pricing Deal Means for People With Obesity

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Compounding Pharmacy Sues Lilly and Novo Nordisk / 4 months

FDA Removes Suicide Warnings from GLP‑1 Drugs / 4 months

Medicare unveils new option for covering weight‑loss drugs for seniors / 22 days

Novo Nordisk slashes prices for Ozempic and Wegovy / 6 months

GLP‑1 drugs associated with lower addiction risk in large study / 2 months

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage / 2 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months